To obtain your CE credit:
Within 48 hours ofthe program's completion, you will receive an email with a link to take the posttest, complete the evaluation, and claim your credit.
Note for ODs: COPE guidelines dictate that in order to receive credit, you must view the program within its required instructional time.
This program has concluded. Thank you for attending. Please select "Next Page" to proceed to the posttest, evaluation, and credit pages.
To obtain your CE credit:
After verification of attendance, within 48 hours of the program's completion, you will receive an email with a link to take the posttest, complete the evaluation, and claim your credit.
Note for ODs: COPE guidelines dictate that in order to receive credit, learners must remain at the in-person event until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
This optometric workshop uses step-by-step video tutorials to showcase the latest in-office ocular surface disease, meibomian gland dysfunction, eyelid management, and cornea disorder diagnostics and treatments as well as keys for educating and communicating with these patients.
This activity is supported by unrestricted educational grants from Alcon, Bausch + Lomb, Johnson & Johnson Vision, RVL, Sight Sciences, Tarsus, and Trukera Medical.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education, LLC is a COPE-accredited administrator.
This activity, COPE Activity Number 124676, is accredited by COPE for continuing education for optometrists. This course is approved for 4 hours CE.
Course #: 80602-TD
Activity #: 124676
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Marc R. Bloomenstein, OD, FAAO
Schwartz Laser Eye Center
Director of Optometric Services
Scottsdale, AZ
Douglas K. Devries, OD
Co-Founder
Eye Care Associates of Nevada
Sparks, NV
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Marc R. Bloomenstein, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Allergan, Azura, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, OcuSoft, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus. Grant/Research: Sight Sciences. Speaker’s Bureau: Allergan, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, Oyster Point Pharma, RVL, Sight Sciences, and Sun Pharmaceutical Industries.
Douglas K. Devries, OD, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Alcon, Allergan/AbbVie, Avellino, Azura Ophthalmics, Bausch Health, BioTissue, Bruder, Dompé, Eyevance Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, Lumenis, Novartis, OcuSoft, Orasis Pharmaceuticals, Oyster Point Pharma, Quidel, Science Based Health, Sun Pharmaceutical Industries, Tarsus, TearLab, TearScience, Théa Pharma, and Visus. Speaker's Bureau: Alcon, Allergan/AbbVie, Bausch Health, BioTissue, Dompé, Eyevance Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, Lumenis, Novartis, OcuSoft, Oyster Point Pharma, Quidel, Science Based Health, Sun Pharmaceutical Industries, and TearScience. Stock/Shareholder: Opthalmic Resources.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Alcon, Bausch + Lomb, Johnson & Johnson Vision, RVL, Sight Sciences, Tarsus, or Trukera Medical.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
NOTE ABOUT OBTAINING CREDIT
Learners must remain at the in-person event until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 creditDeepak Sambhara, MD
